Biotech "Tweets of the Week" for April 6-10, 2015Gene therapy and cancer immunotherapy: again and still.
Featuring: $QURE $BMY $OCUL $DYAX $TRIL $ADXS $XBI $IBB Check out the Biotech Tweets of the Week archive. |
|
$BMY to buy 4.9% stake in $QURE
— Bio Stocks™ (@BioStocks) April 6, 2015
@nixon786 I've $cemp on dips and I like $cfrx which is high risk high reward play on anti biotic resistance
— Joshua B (@srqstockpicker) April 6, 2015
$TRIL 1 picture say it all with over 110% since 02/20 or as my bud @cornel6m scary looking up and dizzy looking down. pic.twitter.com/AaX4z4G3A2
— Joe (@GantosJ) April 6, 2015
$AFMD doing the stealth thing
— Don Shimoda (@zDonShimoda) April 6, 2015
$SSH HOD. Should hear from FDA soon..
— Bio Stocks™ (@BioStocks) April 6, 2015
$CLVS: Breakthrough Therapy Designation Rucaparib for Monotherapy Treatment of Advanced Ovarian Cancer in Patients with BRCA-mutated Tumors
— HumbleBioTrader (@HumbleBioTrader) April 6, 2015
@lomu_j There's a limit to investors' appetite even4 a "winner" stock. $ICPT has raised >$550M in past 2 months.
— Roy Friedman (@DewDiligence) April 6, 2015
$OCUL Data removes overhang BUY on weakness -
Piper Jaffray
Leerink Swandive
HC Wainwright
Roth
— LifeSciencesMkt (@LifeSciencesMkt) April 6, 2015
LOL $OCUL CEO blames site to site variability for trial failure and talks up post-hoc analysis...
— Andy Biotech (@AndyBiotech) April 6, 2015
$SAGE Sage Therapeutics files $100M common stock offering.
— Chill Till (@ChillzTrading) April 7, 2015
$QURE market cap $700m vs. $ONCE 1.85B and $AAVL $1.16B. Hmmmm
— Zack (@BioTerp) April 7, 2015
1 year ago today I started at @CNBC. Thank you for such an incredible one!
— Meg Tirrell (@megtirrell) April 7, 2015
Today I am announcing the launch of a cancer immunotherapy index. http://t.co/phFIIgC2BS
— Brad Loncar (@bradloncar) April 7, 2015
$QURE 33.80
Bumps PT to $50 (from $28)
Reiterates Outperform-rating
-Leerink
— Tom Wrigley (@WrigleyTom) April 7, 2015
$CERU @redacre Perhaps data isn't that impressive given how PD1's have similar ORR in RCC and that's all invstrs are willing to pay
— j l (@lomu_j) April 7, 2015
$RGLS - RG-125 (AZD4076) Selected as Clinical Candidate by AstraZeneca.
— Brandon Hayward (@VexTrades) April 7, 2015
$QURE follow-on offering 3M shares
— Bio Stocks™ (@BioStocks) April 7, 2015
Fun fact: After $QURE closes raise + BMY deal, @ current price, would have ~250m cash @ $800m market cap vs. $ONCE ~$250m cash at $1.9B cap
— Zack (@BioTerp) April 7, 2015
$DYAX prices offering. 7.4M shares at $27/share
— Bio Stocks™ (@BioStocks) April 7, 2015
If you are looking for another undervalued European #immunooncology stock to go with your $MDG position, take a look at $CARD, now #Celyad.
— V.S. Schulz (@portefeuillefun) April 8, 2015
$LBIO..files for resale of 9.5m shares of company's common stock by selling stockholders..looks like an opportunity. On watch!
— Sheff (@SheffStation) April 8, 2015
Can't stand when Cos don't file their K on time. Investors aren't going to take you seriously if you can't even meet basic reporting rules.
— Jason Napodano, CFA (@JNapodano) April 8, 2015
Semi-buried in $HALO's PR is that they still haven't received buy-in on their Dx approach yet. Can't initiate the trial until they do.
— Brad Loncar (@bradloncar) April 8, 2015
$SGYP Adding to swing position on this pullback... getting ready for next leg up
— BioBreakout (@BioBreakout) April 8, 2015
@AndyBiotech i see your $RGLS and raise you $DYAX vs $VPHM
— zach (@zbiotech) April 8, 2015
. @Skipjackrick hope everyone knows when I say slammed the calls. It means I sold them. It's a covered call position.
— Rick (@Skipjackrick) April 8, 2015
$ENTA +12% on the week. EASL data look quite favorable, so far.
— Roy Friedman (@DewDiligence) April 8, 2015
This is the kind of day that makes some of your stupid trades look freakin' brilliant
— Stan D'Andrea, Ph.D. (@stanleydandrea) April 8, 2015
@chessNwine covered $IBB +21.58
— tiger (@tiger_shark5039) April 8, 2015
Just saw a terrible promotional commercial for $CGIX stock on TV.
— Brad Loncar (@bradloncar) April 8, 2015
$OVAS trying to find a bottom. 200SMA good level to shoot against.
— CashRocket (@CashRocket) April 8, 2015
For once $KITE is actually outperforming $JUNO.
— Brad Loncar (@bradloncar) April 8, 2015
@redacre @bradloncar I like $KITE at $58 much more than buying $JUNO now. I also like that $KITE will have multiple Ph3s running this yr.
— Keith Abrams (@DeepSouthDoctor) April 8, 2015
$tril highest closing price at 26.70 today #trillen
— Joshua B (@srqstockpicker) April 8, 2015
Didn't expect $MRK to close in red the day it released the highly anticipated Hep C phase 3 results.
— avidresearch (@avidresearch) April 8, 2015
Huge day! $ONVO $RGLS $ATNM $KITE $TTOO $GERN all went big today. $OSUR $RPRX $VNDA $PDLI $MEIP $AEGR could be next if bio bounce continues
— S Manian (@DrSManian) April 8, 2015
$GWPH Piper Jaffray reiterates overweight & $147 PT.
— Joe (@Drchik23) April 9, 2015
$AUPH chart broke on expansive volume, I'll be adding. But.. it is early in the game. would rather see a base or upward momentum. 7% pos
— Olddogwithnewtrix (@olddoggnewtrix) April 9, 2015
@VikramKhanna_ ah tulip mania is back in biotech land
— Sally Church (@MaverickNY) April 9, 2015
.@zbiotech Let’s form a company to develop a highly effective placebo. I’m sure we could get funding & IPO under ticker $DUMB
— Adam Feuerstein (@adamfeuerstein) April 9, 2015
$CRMD files $100M shelf and $40M ATM. I guess that sale process is going super well.
— Adam Feuerstein (@adamfeuerstein) April 9, 2015
aberrant and disproportional moves are a key theme these days for scangos's affiliations $EXEL $BIIB
— zach (@zbiotech) April 9, 2015
@srqstockpicker @AdamSinger it was my top lotto play for 2014 and 2015. definitely the longest I've ever held a large position )) $TRIL
— Olddogwithnewtrix (@olddoggnewtrix) April 9, 2015
When those green lights start blinking at you, retail buys, pros sell!
— HumbleBioTrader (@HumbleBioTrader) April 9, 2015
@bradloncar all the computers did (-:
— Ivan Bunin (@TheVillageSpy) April 9, 2015
$CLDN now has given back the ENTIRE run-up since middle Feb
— Shane Blackmon (@shaneblackmon) April 9, 2015
$CLDN down another 5% today. Traders rushing out.
— Juan P. Serrate, DVM (@JPZaragoza1) April 9, 2015
$ACAD looking like the market believes in DAVIS! Nice rebound from 29 few weeks ago
— dougheuring (@dougheuringaria) April 9, 2015
@modern_rock @super_trades my only regret in life is not owning more $TRIL.
— Adam Singer (@AdamSinger) April 9, 2015
$SHPG just gained ~$3B in mkt cap on lifitegrast priority review, should help those vouchers that are waiting for sale ;) --> $UTHR $RTRX
— Andy Biotech (@AndyBiotech) April 9, 2015
Sold $SSH at 4.68 from 5.56 buy a few weeks ago. That was fun.
— Greg (@ggl26) April 9, 2015
@JasonCRG @BioTerp I like the risk/reward at these levels a lot. Bi-specifics undervalued and $AFMD undervalued for bispecifics.
— David Sobek (@dsobek) April 9, 2015
@VikramKhanna_ End stage behavior. Deals that rely on institutional buying die on the vine, junk goes parabolic as retail takes over.
— BuyersStrike (@BuyersStrike) April 9, 2015
$MDCO guides way down on Angiomax, citing customer concerns over IP this year. Wouldn't the dollar have been an easier out?
— PropThink (@PropThinker) April 9, 2015
.@cboe start option chains for $OTIC
— E B (@Mazmasta) April 9, 2015
Eisai firing 25% of its U.S workforce because Belviq is a blockbuster obesity drug. $ARNA
— Adam Feuerstein (@adamfeuerstein) April 9, 2015
.@dsobek @JasonCRG @BioTerp I'm partial to $MGNX + $IPH.PA = $AFMD
— Don Shimoda (@zDonShimoda) April 9, 2015
Can't believe #AACR15 is coming up so quickly already. Especially when NY feels more like November than spring brrr
— Sally Church (@MaverickNY) April 9, 2015
@KlaipedaBorn @DrSManian $CEMP $TTPH will face same issue too.
— BioBounce.com (@BioBounce) April 10, 2015
$ADXS gives shout out to LCINDX http://t.co/BKUl82nkan
— j l (@lomu_j) April 10, 2015
$QURE prices 3M shares at $29.50/share
— Andy Biotech (@AndyBiotech) April 10, 2015
LOL $CBMX up 20%+ on PR for a NEJM paper that was published a week ago, not to mention the paper was from a big competitor (Roche/Ariosa)...
— Andy Biotech (@AndyBiotech) April 10, 2015
People should pay attention to $ADMS - I guess I said it before
— Alfredo Fontanini (@AF_biotech) April 10, 2015
If $IBB remains strong I plan to play $QURE long against the offering pricing of 29.50.
— Cody (@codytrades) April 10, 2015
Btw credit of $ADMS idea should go to @GantosJ - he's the one who put it on my radar. I just did dd and emphasized pros and cons
— Alfredo Fontanini (@AF_biotech) April 10, 2015
H/T to @olddoggnewtrix on $auph he has done some great DD on this one
— Joshua B (@srqstockpicker) April 10, 2015
@adamfeuerstein @lomu_j @Sharma1981N all biotech drugs are probabilistic. Some are 99.99% sure whereas others are as low as 99.91%
— David Sobek (@dsobek) April 10, 2015
Friday biotech humor. pic.twitter.com/8TbQHVCt4X
— Bruce Booth (@LifeSciVC) April 10, 2015